The FDA just approved a digital pill that tracks when you take it. Elizabeth Keatinge (@elizkeatinge) has more.
The U.S. Food and Drug Administration approved a joint application by Proteus Digital Health and Otsuka Pharmaceutical for a medication monitoring tool for patients taking Otsuka’s drug Abilify. The drug is geared for people with schizophrenia, bipolar disorder and in some cases, depression.
Sensors, developed by Proteus Digital Health, are embedded in the pills and activated by stomach juices. The sensor transmits signals to a wearable with an electrode in the form of a skin patch. Data such as vital signs, body position, and verification of medication ingestion are wirelessly transmitted with the help of the wearable.
The FDA approval came with some caveats regarding the technology’s limitations, though. It noted that the ability of the sensors to track the patient’s compliance with their treatment regimen “has not been shown”.
Video by Veuer/Elizabeth Keatinge[/vc_message]
Disclaimer
The information contained in South Florida Reporter is for general information purposes only.
The South Florida Reporter assumes no responsibility for errors or omissions in the contents of the Service.
In no event shall the South Florida Reporter be liable for any special, direct, indirect, consequential, or incidental damages or any damages whatsoever, whether in an action of contract, negligence or other tort, arising out of or in connection with the use of the Service or the contents of the Service. The Company reserves the right to make additions, deletions, or modifications to the contents of the Service at any time without prior notice.
The Company does not warrant that the Service is free of viruses or other harmful components
